Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supreme Court Upholds IPR Standard Making Patent Invalidation Easier; Will Congress Reverse?

This article was originally published in The Pink Sheet Daily

Executive Summary

High court says inconsistent decisions by Patent Trial and Appeal Board and district court are okay; House and Senate bills would eliminate the broad standard but opposition by tech community could doom passage.

You may also be interested in...



US Supreme Court Seems Poised To Allow Patent Holders More Judicial Review Options

In case that could impact challenges of biopharma patents, Supreme Court questioned the consequences of not allowing courts to review PTAB institution decisions when petition may be time barred.

PTO Final Rule Dropping BRI Patent Claim Standard Offers No Deference To District Courts

Patent office may issue guidance on how PTAB will consider prior claim constructions; actions on other procedures may be coming in the 'near future.'

US Patent Reform Debate: Proposal To Eliminate BRI Patent Claim Standard Splits Stakeholders

BIO and PhRMA want PTAB to give district courts deference in construing patent claims; Rep. Lofgren is concerned PTAB will be prohibited from doing its own claim construction and Mylan cites potential for inconsistencies within PTO.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS079531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel